Early central nervous system involvement in adults with acute non-myelogenous leukaemia.
Of 47 consecutive patients aged 15-60 years with acute non-myelogenous leukaemia (ANML) (40 acute lymphoblastic leukaemia (ALL); 5 acute Burkitt-like leukaemia (ABLL), 2 acute undifferentiated leukaemia (AUL) treated with a standard chemotherapy protocol (OPAL), 31 achieved complete remission (28/40(70%) of patients with ALL). CNS leukaemia occurred in 4/16 non-remitters, and in 6 patients who achieved complete remission (CR). CNS leukaemia occurred in all 5 patients with acute Burkitt-like leukaemia. 4/28 patients with ALL achieving CR had evidence of CSF involvement on cytocentrifuge examination shortly after CR. The apparent risk of early CNS disease suggests that prophylactic CNS therapy should be given early in the treatment of acute non-myelogenous leukaemia.
D000293:Adolescent; D000328:Adult; D001215:Asparaginase / Q000627:therapeutic use; D002493:Central Nervous System Diseases; D006801:Humans; D007945:Leukemia, Lymphoid / Q000134:cerebrospinal fluid / Q000188:drug therapy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011239:Prednisolone / Q000627:therapeutic use; D012075:Remission, Spontaneous
D011239:Prednisolone; D001215:Asparaginase
Cancer Chemother Rep. 1964 Nov;42:25-8
14226126
Blood. 1973 Dec;42(6):935-8
4519105
Blood. 1973 Sep;42(3):349-57
4516522
Cancer. 1974 Mar;33(3):863-9
4521890
Cancer. 1972 Feb;29(2):381-91
4501697
Cancer. 1974 Aug;34(2):418-26
4527793
Cancer. 1975 Aug;36(2):770-4
1080431
Cancer. 1975 Aug;36(2):775-95
1057450